Study guide

17.3 Medical Cannabis, Legalization Policy, Adolescent Risk & Patient Education

Certified Addictions Registered Nurse - Advanced Practice CARN-AP

Track your progress as you read

Finished sections get a check mark.

1 Introduction: The CARN-AP Examination & Foundations of Advanced Addictions Practice

About the CARN-AP Examination: Blueprint, Scoring & Eligibility The Neurobiology of Addiction: Binge, Withdrawal & Preoccupation Screening, SBIRT & the ASAM Criteria Levels of Care

2 Chapter 1: Opioid Use Disorder: Assessment, Overdose Response & Methadone Maintenance

1.1 OUD Assessment, DSM-5-TR Diagnostic Criteria, and Clinical Opiate Withdrawal Scale (COWS) 1.2 Methadone Pharmacology, OTP Federal Regulations, QTc Prolongation & CYP450 Interactions 1.3 Opioid Overdose Assessment, Harm Reduction, Naloxone Formulations & Nalmefene

3 Chapter 2: Buprenorphine Protocols, Long-Acting Injectables & Naltrexone

2.1 Buprenorphine Pharmacology, Standard Office/Home Induction & Precipitated Withdrawal Management 2.2 Low-Dose Micro-Induction (Bernese Method) & Fentanyl Transition Strategies 2.3 Long-Acting Injectable Buprenorphine (Sublocade, Brixadi) & Extended-Release Naltrexone (Vivitrol)

4 Chapter 3: Alcohol Use Disorder: Neurobiology, Assessment & Acute Withdrawal

3.1 AUD Neurobiology, Epidemiology, Screening Instruments (AUDIT, AUDIT-C, CAGE) & Laboratory Biomarkers 3.2 Alcohol Withdrawal Syndrome, CIWA-Ar Protocol, Symptom-Triggered Benzodiazepine Regimens & Delirium Tremens 3.3 Wernicke-Korsakoff Syndrome, High-Dose Parenteral Thiamine Protocols & Acute Medical Complications

5 Chapter 4: Medications for Alcohol Use Disorder (MAUD)

4.1 Oral and Injectable Naltrexone for AUD: Mechanism, Prescribing Protocols & Clinical Efficacy 4.2 Acamprosate Calcium: NMDA Modulation, Renal Dosing Parameters & Abstinence Maintenance 4.3 Disulfiram and Second-Line / Off-Label MAUDs: Topiramate, Gabapentin & Baclofen

6 Chapter 5: Stimulant, Sedative-Hypnotic & Synthetic Substance Use Disorders

5.1 Stimulant Use Disorder (Cocaine & Methamphetamine): Neurotoxicity, Medical Emergencies & Evidence-Based Interventions 5.2 Sedative, Hypnotic, and Anxiolytic Disorders: Dependence Physiology, Risks & Outpatient Tapering Protocols 5.3 Emerging Synthetic Drugs: Fentanyl Analogues, Synthetic Cathinones, Cannabinoids & Xylazine-Associated Necrotic Wounds

7 Chapter 6: Tobacco and Cannabis Use Disorders: Evidence-Based Pharmacotherapy & Interventions

6.1 Tobacco Use Disorder & Nicotine Dependence: Dual NRT, Varenicline & Bupropion Prescribing Protocols 6.2 Cannabis Use Disorder, Synthetic Cannabinoids & Cannabinoid Hyperemesis Syndrome 6.3 Behavioral Therapies in Substance Use: Motivational Interviewing, CBT & Contingency Management

8 Chapter 7: Psychiatric Differential Diagnosis & Medical Mimics in Addictions

7.1 Diagnostic Formulation: Primary vs. Substance-Induced Psychiatric Disorders & The 30-Day Rule 7.2 Endocrine, Neurological, and Metabolic Mimics of Substance Intoxication and Withdrawal 7.3 Decisional Capacity, Competency, and Involuntary Commitment in Acute Addiction Practice

9 Chapter 8: Co-Occurring Psychiatric Disorders: Integrated Treatment Planning

8.1 Integrated Dual Diagnosis Treatment (IDDT) Framework & High-Prevalence Mood / Anxiety Co-Occurring Disorders 8.2 Complex Severe Mental Illness: Psychotic Disorders, Bipolar Disorder & Borderline Personality in Addictions 8.3 Trauma-Informed Care, PTSD, and Addictions: Evidence-Based Integrated Psychotherapy

10 Chapter 9: Pain Management in Substance Use Disorders & CDC 2022 Guidelines

9.1 CDC 2022 Clinical Practice Guideline for Prescribing Opioids for Chronic Pain: Individualized Assessment vs. Hard Caps 9.2 Multimodal Non-Opioid Pharmacotherapy, Interventional Modalities & Non-Pharmacological Strategies 9.3 Acute Pain Management in Patients on Maintenance MOUD (Methadone, Buprenorphine, Naltrexone)

11 Chapter 10: Perinatal Substance Use, Neonatal Abstinence & Infectious Complications

10.1 Perinatal Substance Use Disorder: ACOG/ASAM Guidelines, MOTHER Trial & Maintenance MOUD 10.2 Neonatal Abstinence Syndrome (NAS/NOWS): Finnegan Scoring vs. Eat, Sleep, Console (ESC) & Breastfeeding 10.3 Infectious Complications in People Who Inject Drugs: Viral Hepatitis, HIV, Endocarditis & PrEP/PEP

12 Chapter 11: Federal Regulations, Confidentiality & Controlled Substance Prescribing

11.1 Controlled Substances Act, DEA Registration, Schedule Classifications & MAT Act of 2023 11.2 Confidentiality of Substance Use Disorder Patient Records: 42 CFR Part 2 (2024 Final Rule) & HIPAA Harmonization 11.3 Prescription Drug Monitoring Programs (PDMP) & Urine Drug Testing (UDT) Interpretation

13 Chapter 12: APRN Scope of Practice, Ethical Foundations, Harm Reduction & Research Literacy

12.1 APRN Scope of Practice, Prescriptive Authority & Collaborative Practice Regulations 12.2 Ethical Dilemmas in Addictions Nursing: Stigma, Autonomy, Justice, and Maternal/Fetal Rights 12.3 Harm Reduction Philosophy, Syringe Service Programs, Drug Checking & Overdose Prevention 12.4 Landmark Clinical Trials & Research Literacy in Addictions Medicine

14 Chapter 13: Stimulant Use Disorder in Depth — Methamphetamine, Withdrawal, Treatment & Harm Reduction

13.1 Methamphetamine Use Disorder: Pharmacology, Medical & Psychiatric Sequelae 13.2 Stimulant Withdrawal, Craving & Contingency Management 13.3 Pharmacotherapy Research for Stimulant Use Disorder 13.4 Stimulant Harm Reduction, Overamping & Patient Education

15 Chapter 14: Medical Consequences of Alcohol Use — Liver, Heart, Cancer & Nutrition

14.1 Alcohol-Associated Liver Disease: Staging, Scoring & Management 14.2 Cardiovascular, Oncologic & Nutritional Consequences of Alcohol

16 Chapter 15: Brief Intervention, Drinking Goals & Recovery Support in Alcohol Use Disorder

15.1 Brief Intervention, Drinking Goals & Shared Decision Making in AUD 15.2 Relapse Prevention, Mutual-Help Programs & Recovery Support

17 Chapter 16: Tobacco Use Disorder in Depth — Neurobiology, Assessment & Special Populations

16.1 Nicotine Neurobiology, Epidemiology & the Tobacco Product Landscape 16.2 Tobacco Assessment & Behavioral Treatment: 5 A's, Quitlines & Incentives 16.3 Tobacco Treatment in Special Populations & Co-Occurring Disorders

18 Chapter 17: Cannabis Use Disorder in Depth — Products, Treatment & Policy

17.1 Cannabinoid Pharmacology, Potency & the Modern Product Landscape 17.2 Cannabis Use Disorder: Epidemiology, Assessment & Treatment Evidence 17.3 Medical Cannabis, Legalization Policy, Adolescent Risk & Patient Education

19 Chapter 18: Other Use Disorders — Inhalants, Hallucinogens, Process Addictions & Prescription/OTC Misuse

18.1 Inhalant Use Disorder: Volatile Solvents, Nitrous Oxide & Alkyl Nitrites 18.2 Hallucinogens & Dissociatives: Classic Psychedelics, PCP, Ketamine & HPPD 18.3 Process (Behavioral) Addictions: Gambling Disorder, Gaming & Compulsive Behaviors 18.4 Prescription & Over-the-Counter Substance Misuse: Opioids, Stimulants, Kratom & DXM

20 Chapter 19: Educating Patients, Families & the Public (CARN-AP Activity Area III)

19.1 Designing Health Teaching: Literacy, Readiness, Culture & Teach-Back 19.2 Medication Education, Informed Consent & Informed Refusal 19.3 Family & Support-System Education: CRAFT, Al-Anon & Overdose Prevention Teaching 19.4 Public, Professional & Anticipatory Guidance: Prevention and Advocacy Teaching

21 Chapter 20: Consultation, Collaboration & Care Coordination (CARN-AP Activity Area IV)

20.1 The APRN Consultation Process & Communicating Recommendations 20.2 Interprofessional Collaboration, Care Coordination & Transitions of Care 20.3 Community Resources, Systems Navigation & Collaborative Documentation

22 Chapter 21: Quality Improvement, Evidence & Leadership in Addictions Nursing (CARN-AP Activity Area V)

21.1 Outcome Measurement & Continuous Quality Improvement in Addictions Care 21.2 Policy Advocacy, Leadership & the Determinants of Addiction

17.3 Medical Cannabis, Legalization Policy, Adolescent Risk & Patient Education

Key Takeaways Explain This Topic AI

State medical cannabis programs authorize possession under state law but do not make any cannabis product FDA-approved, and APRNs certify qualifying conditions rather than writing prescriptions.

Effective April 28, 2026, marijuana in an FDA-approved drug product and marijuana subject to a qualifying state medical marijuana license moved to Schedule III, while all other marijuana remains Schedule I.

Cannabis use in adolescence is associated with a dose-dependent increase in risk of psychotic disorders, with the largest associations for daily high-potency use.

Prenatal cannabis exposure is associated with lower birth weight and neurodevelopmental concerns, and THC concentrates in breast milk, so ACOG advises against use in pregnancy and lactation.

Cannabis roughly doubles motor vehicle crash risk and combines more than additively with alcohol, and there is no blood THC threshold that reliably defines impairment.

Last updated: September 2026

17.3 Medical Cannabis, Legalization Policy, Adolescent Risk & Patient Education

Quick Answer: State medical cannabis programs let an authorized clinician certify a qualifying condition ; they do not create a prescription and do not make any product FDA-approved . Federal status changed on April 28, 2026 , when marijuana in an FDA-approved drug product and marijuana subject to a qualifying state medical marijuana license moved to Schedule III , while all other marijuana — including adult-use and bulk marijuana — remains Schedule I . Cannabis in adolescence carries a dose-dependent association with psychotic disorders. ACOG advises against use in pregnancy and lactation. Cannabis roughly doubles crash risk and there is no reliable blood THC impairment threshold .

1. Certification Is Not Prescription

  • Feature Prescription drug State medical cannabis
  • Federal approval FDA-reviewed for safety and efficacy None for whole-plant products
  • Clinician action Writes a prescription Certifies a qualifying condition under state law
  • Product standardization Strength, purity and bioequivalence regulated Varies by state program and dispensary
  • Dose Specified Patient-selected in practice

Pharmacist role Dispenses with counseling and interaction checking Dispensary staff are typically not licensed pharmacists

APRN eligibility to certify varies widely by state — some programs allow APRNs to certify independently, some require physician involvement, and some exclude APRNs entirely. Verify current state law before certifying; this is a scope-of-practice question, not a clinical one.

2. Where the Evidence Is Strongest and Weakest

  • Indication Evidence position
  • Chemotherapy-induced nausea and vomiting Supported (FDA-approved synthetic agents exist)

Chronic pain, especially neuropathic Modest benefit in meta-analysis; effect sizes smaller than patients expect

  • Multiple sclerosis spasticity Supported for nabiximols where available
  • Rare epilepsy syndromes Supported for purified cannabidiol (Epidiolex)

PTSD, anxiety, depression, sleep Weak or absent; these are among the most common qualifying conditions and have the least support

Opioid sparing Population-level claims have not held up in longitudinal individual-level studies

The honest counseling statement: "For a few conditions there is real evidence. For the conditions most people are certified for, the evidence is thin, and there is a real risk of developing a cannabis use disorder — especially if you use daily or use concentrates."

3. Adolescent Risk

Psychosis: cannabis use is associated with increased risk of psychotic disorders in a dose-dependent pattern, with the strongest associations for daily use of high-potency products . Risk is concentrated in people with genetic vulnerability and early onset. The association does not establish causation in any individual case, but it is strong enough to warrant explicit counseling for adolescents and for anyone with a family history of psychosis.

Cognition: heaviest effects on attention, learning and processing speed during active use and early abstinence; substantial recovery with sustained abstinence, though debate continues about residual effects with very early onset.

Education and employment: dose-dependent associations with school dropout and reduced attainment.

Route matters: dabbing concentrates and using high-concentration vape cartridges produce far higher exposure than flower and are increasingly the adolescent norm.

4. Pregnancy and Lactation

ACOG advises against cannabis use in pregnancy and lactation , and recommends against "medical" cannabis in pregnancy in favor of alternative therapies with better safety data.

Prenatal exposure is associated with lower birth weight and neurodevelopmental concerns.

THC concentrates in breast milk and is detectable for days to weeks; the infant's brain is undergoing rapid development.

Cannabis is commonly used for hyperemesis gravidarum , creating a diagnostic trap: persistent vomiting in a pregnant daily cannabis user may be cannabinoid hyperemesis syndrome , not hyperemesis gravidarum.

Counsel without threat. In many jurisdictions a positive toxicology result triggers a child-welfare report, and patients know it — which is exactly why disclosure requires a trust-first approach and clear information about what the APRN is and is not required to report.

5. Driving

Cannabis approximately doubles motor vehicle crash risk.

Combining cannabis with alcohol produces impairment greater than either alone .

Blood THC concentration correlates poorly with impairment , particularly in chronic users who maintain measurable levels while not acutely impaired. Per se blood THC limits in some states are therefore scientifically contested.

Practical counseling: impairment after inhaled use persists well beyond the subjective "high," and after edibles it can last much longer. The defensible advice is not to drive for several hours after inhaled use and considerably longer after oral use , and never to combine with alcohol.

6. A Compact Patient Education Script

Legal status: "State law and federal law are not the same, and as of 2026 only part of the federal picture changed. Employment, firearms, housing and immigration consequences can still follow."

Potency: "What is sold now is several times stronger than what existed when most of the research was done. Concentrates are stronger still."

Route: "Edibles take up to two hours. Most bad reactions come from eating more during that wait."

Who should be most careful: "People under 25, people with a family history of psychosis, people who are pregnant or breastfeeding, and anyone using daily."

Driving: "There is no reliable number for cannabis like there is for alcohol. Give it hours, and never mix it with drinking."

Teach-back: ask the patient to state, in their own words, the two things they will change.